Answer
Tibsovo (ivosidenib), combined with azacitidine, is indicated for adults with newly diagnosed acute myeloid leukaemia with an IDH1 R132 mutation who are not eligible for standard induction chemotherapy.
Sources for this answer
- TibsovoServier Laboratories Limited · emc · SmPC §4.1 Therapeutic Indications · Version 5Document updated
Sources checked